Sitemap > Breaking Research > Metabolic & Hormonal Disorders
Displaying 1651 - 1700 of 3753 results
- Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.
- Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
- Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
- Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARalpha/gamma dual agonists.
- Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.
- 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
- Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
- Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
- Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
- Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists.
- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
- Sensory neurons link the nervous system and autoimmune diabetes.
- Ischemia/reperfusion injury: The role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation.
- Quinazoline and benzimidazole MCH-1R antagonists.
- Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
- Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
- Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
- Valsartan treatment reverses erectile dysfunction in diabetic rats.
- Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats.
- Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR).
- Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
- Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection.
- Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
- Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.
- Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activators.
- Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis.
- AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes.
- Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat.
- Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
- A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human.
- Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
- Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
- A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
- Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
- Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
- Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity.
- Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
- Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus.
- Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
- 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
- Renin receptor expression in human adipose tissue.
- Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes.
- Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
- Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
- Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
- Recombinant annexin-2 inhibits the progress of diabetic nephropathy in a diabetic mouse model via recovery of hypercoagulability.
- New beta-alanine derivatives are orally available glucagon receptor antagonists.
- Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
- Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats.
- Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 Next >